Prognostic analysis of cutaneous Kaposi sarcoma based on a competing risk model

被引:0
作者
Bei Qian
Ying Qian
Peng Xiao
Liang Guo
机构
[1] Huazhong University of Science and Technology,Department of Thyroid and Breast Surgery, Union Hospital, Tongji Medical College
[2] Yangtze University,Department of Pharmacy, Jingzhou Hospital
[3] Huazhong University of Science and Technology,Department of Plastic Surgery, Union Hospital, Tongji Medical College
来源
Scientific Reports | / 13卷
关键词
D O I
暂无
中图分类号
学科分类号
摘要
The data regarding the prognosis of cutaneous Kaposi sarcoma (KS) was limited. The current study aimed to explore the risk factors and develop a predictive model for the prognosis of cutaneous KS patients. Data were extracted from Surveillance, Epidemiology, and End Results database from 2000 to 2018 and randomly divided into training and validation cohort. The Kaplan–Meier analysis, cumulative incidence function based on the competing risk model and Fine–Gray multivariable regression model was used to identify the prognostic factors and then construct a 5-, 10-, and 15-year KS-specific death (KSSD) nomogram for patients. The concordance index (C-index), area under the curve (AUC) of operating characteristics and calibration plots were used to evaluate the performance of the model. The clinical utility of the model was measured by decision curve analysis (DCA). In 2257 cutaneous KS patients identified from database, the overall median survival time was about 13 years. Radiotherapy (p = 0.013) and surgery (p < 0.001) could lower the KSSD, while chemotherapy (p = 0.042) and surgery (p < 0.001) could increase the overall survival (OS) of patients with metastatic and localized lesions, respectively. Race, number of lesions, surgery, extent of disease, year of diagnosis and age were identified as risk factors associated with cutaneous KS-specific survival. Performance of the nomogram was validated by calibration and discrimination, with C‐index values of 0.709 and AUC for 5-, 10-, and 15-year-KSSD of 0.739, 0.728 and 0.725 respectively. DCA indicated that the nomogram had good net benefits in clinical scenarios. Using a competing-risk model, this study firstly identified the prognostic factors, and constructed a validated nomogram to provide individualized assessment and reliable prognostic prediction for cutaneous KS patients.
引用
收藏
相关论文
共 81 条
[1]  
Cesarman E(2019)Kaposi sarcoma Nat. Rev. Dis. Primers 5 9-542
[2]  
Vangipuram R(2019)Epidemiology of Kaposi sarcoma: Review and description of the nonepidemic variant Int. J. Dermatol. 58 538-517
[3]  
Tyring SK(2019)Kaposi sarcoma updates Dermatol. Clin. 37 505-1319
[4]  
Etemad SA(2020)Isolated limb perfusion is an effective treatment modality for locally advanced Kaposi sarcoma of the extremities Eur. J. Surg. Oncol. 46 1315-1284
[5]  
Dewan AK(2021)Nodular endemic Kaposi sarcoma successfully treated with Mohs micrographic surgery Dermatol. Surg. 47 1283-762
[6]  
Boere T(2011)Cancer burden in the HIV-infected population in the United States J. Natl. Cancer Inst. 103 753-422
[7]  
Rigo R(2013)Kaposi's sarcoma: Etiology and pathogenesis, inducing factors, causal associations, and treatments: facts and controversies Clin. Dermatol. 31 413-685
[8]  
Lee A(2004)Lymphatic reprogramming of blood vascular endothelium by Kaposi sarcoma-associated herpesvirus Nat. Genet 36 683-1041
[9]  
Minkis K(2018)HIV-Associated cancers and related diseases N. Engl. J. Med. 378 1029-4247
[10]  
Shiels MS(2019)A pilot study of liposomal doxorubicin combined with bevacizumab followed by bevacizumab monotherapy in patients with advanced Kaposi sarcoma Clin. Cancer Res. 25 4238-1580